Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

- PMLiVE

Eisai sues DEA over Fycompa scheduling

Pharma company won FDA approval in 2012 but still lacks DEA verdict

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

- PMLiVE

Mobile campaign aims to tackle childhood obesity

OpenMarket to run programme for Blue Cross of Idaho Foundation

EISAI

Eisai’s epilepsy drug Zonegran wins Swiss approval

Swissmedic licences new monotherapy indication for the treatment

- PMLiVE

US increases pressure on India over generics industry

Follows complaints from Pfizer about the country’s patent laws

- PMLiVE

Eisai pulls epilepsy drug Fycompa in Germany

Based on unfavourable assessment by pricing body

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

Novo Nordisk on track to file liraglutide in obesity

Expects regulatory filings in the US and EU by the beginning of 2014

- PMLiVE

GSK awarded $200m by US government for antibiotic research

Follows state-supported schemes in Europe to combat resistance to antibiotics

- PMLiVE

Research units to close as Astellas restructures

US subsidiaries OSI Pharmaceuticals and Perseid Therapeutics among those affected

- PMLiVE

Belviq cleared for US launch after abuse risk determined

Drug Enforcement Administration says Arena's weight loss drug has relatively low risk of abuse

- PMLiVE

Arena pulls obesity drug Belviq application in EU

EMA asks for more data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links